COVID-19 Demand Gives Lupin Optimism On Albuterol

Metformin Batch Likely To Be Recalled

Lupin hopes a surge in demand for albuterol sulphate due to increased off-label use in COVID-19 patients will help its generic version, which is likely to be launched in the first half of FY21. But the Indian firm may recall a batch of metformin after the US FDA recently asked a few companies to retract extended-release versions due to NDMA concerns.

Covid19_Lungs_Vial
Off-label Use Of Albuterol For COVID-19 Has Upped Demand • Source: Shutterstock

More from Strategy

More from Business